TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
A Phase 1/2, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
Sponsor: Merck Sharp & Dohme LLC
Terminated
Company operational decision. Decision to stop study is not due to safety or efficacy concerns.
Other terminated trials from Merck Sharp & Dohme LLC
- Melanoma · Phase PHASE2 · Feb 2026
- Advanced Solid Tumor · Phase PHASE2 · Jan 2026
- Lung Cancer Metastatic · Phase PHASE1/PHASE2 · Dec 2025
- Advanced and Metastatic Urothelial Cancer · Phase PHASE2 · Sep 2025
- Malignant Solid Tumor · Phase PHASE1 · Aug 2025
More terminations from Merck Sharp & Dohme LLC
A PHASE1/PHASE2 clinical study on Advanced Cancer and Advanced Solid Tumor, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 2 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
2 versions recorded-
Dec 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Terminated PHASE1/PHASE2
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- Teon Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .